Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon

Leukemia

Volumn 12, Issue 2, 1998, Pages 155-163

  Oka, T ^a,d   Sastry, K J ^b   Nehete, P ^b   Schapiro, S J ^b   Guo, J Q ^a   Talpaz, M ^a   Arlinghaus, R B ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

BCR ABL; Cellular immunity; CML; IFN

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA TRANSFECTION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; MONKEY; MONONUCLEAR CELL; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 0031885797     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400919     Document Type: Article

References (26)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1499.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
3. Shtivelman E, Lifschitz B, Gale RP, Canaani E. Fused transcript of abland bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550-554.
4. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984; 37: 1035-1042.
5. Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Arlinghaus R. The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity. Virology 1985; 110: 230-238.
6. Hermans AS, Heisterkamp N, von Lindern M, vanBaal S, Meijer D, van der Plas D, Wiedemann LM, Groffen J, Bootsma D, Grosveld G. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33-40.
7. Kantarjian HM, Deisseroth AB, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia; a concise update. Blood 1993; 82: 691-703.
8. Dhingra K, Kurzrock R, Baine R, Eastman S, Kantarjian H, Gutterman JU, Talpaz M. Minimal residual disease in interferontreated chronic myelogenous leukemia; results and pitfalls of analysis based on polymerase chain reaction. Leukemia 1992; 6: 754-757.
9. Talpaz M, Estrov Z, Kantarjian H, Ku S, Foteh A, Kurzrock R. Persistence of dormant leukemic progenitors during interferoninduced remission in chronic myelogenous leukemia. J Clin Invest 1994; 94: 1383-1389.
10. Chen W, Peace DJ, Rovira D. T-cell immunity to the joining region of P210 BCR-ABL protein. Proc Natl Acad Sci USA 1992; 89: 1468-1472.
11. Barrett AJ, Jiang YZ, Kars A, Gordon AA, Datta A. HLA DR-4 restricted T-lymphocytes recognize decapeptides representing the novel fusion region of the BCR-ABL protein in CML. J Cell Biochem 1992; 16D (Suppl.): 26 (Abstr.).
12. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-334.
13. Smith RG, Dev VG, Shannon WA Jr. Characterization of a novel pre-B leukemia cell line. J Immunol 1981; 126: 596-602.
14. Merrifield RB. Solid phase peptide synthesis. J Am Chem Soc 1963; 85: 2149-2154.
15. Houghten RA. General method for the rapid solid-phase synthesis of large numbers of peptides; specificity of antigen-antibody interaction at the level of individual amino acids. Proc Natl Acad Sci USA 1985; 76: 4350-4354.
16. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989, p 16.42.
17. Lu D, Liu J, Campbell M, Guo JQ, Heisterkamp N, Groffen J, Cannani E, Arlinghaus RB. Tyrosine phosphorylation of p160BCR by P210 BCR-ABL. Blood 1993; 82: 1257-1263.
18. Nehete PN, Johnson PC, Shapiro SJ, Arlinghaus RB, Sastry KJ. Cross reactive T-cell proliferative responses to V3 peptides corresponding to different geological HIV-1 isolates in HIV-seropositive individuals. J Clin Immunol 1996; 16: 115-124.
19. Thiele DL, Kurosaka M, Lipsky PE. Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood; delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol 1993; 131: 2282-2290.
20. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
21. CLIO JQ, Lian JY, Xian YM, Lee M-S, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JYJ, Arlinghaus RB. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994; 83: 3629-3637.
22. Fisk B, Blevins TL, Wharton JT, Ioannides CC. Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-2117.
23. Ioannides CG, Ioannides MC, O'Brian CA. T cell recognition of oncogene products: a new strategy for immunotherapy. Mol Carcinogen 1992; 6: 77-82.
24. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA. In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Cancer Res 1994; 54: 1071-1076.
25. ten Bosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia 1995; 9: 1344-1348.
26. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996; 87: 3587-3592.